IL10 and COVID-19: Although IL-10 is conventionally known as an anti-inflammatory cytokine, the rapid early rise appears to be a distinguishing feature of hyperinflammation during severe COVID-19 (66), and several studies have demonstrated that IL-10 levels are associated with poor outcomes in patients with COVID-19 (13, 63, 65, 67, 68).